Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy

Current Opinion in Obstetrics and Gynecology

Volumn 27, Issue 1, 2015, Pages 98-107

  Lambertini, Matteo ^a,b   Ginsburg, Elizabeth S ^c   Partridge, Ann H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BRCA1 and BRCA2 mutations; breast cancer; fertility issues; ovarian cancer; young women

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; GONADORELIN DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CRYOPRESERVATION; DRUG EFFICACY; FEMALE; FERTILITY PRESERVATION; GENE MUTATION; GYNECOLOGIC SURGERY; HUMAN; ONCOGENE; OVARY CANCER; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; ANIMAL EMBRYO; BREAST NEOPLASMS; DIRECTIVE COUNSELING; OOCYTE; OVARIAN NEOPLASMS; PATIENT EDUCATION; RISK REDUCTION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CRYOPRESERVATION; DIRECTIVE COUNSELING; EMBRYO, MAMMALIAN; FEMALE; FERTILITY PRESERVATION; GENES, BRCA1; GENES, BRCA2; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; OOCYTES; OVARIAN NEOPLASMS; PATIENT EDUCATION AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 84920832832     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000138     Document Type: Review

References (95)

1. Surveillance, Epidemiology, and End Results Program. http://seer.cancer. gov/. [Accessed 18 October 2014]
2. Martínez F, Devesa M, Coroleu B, et al. Cancer and fertility preservation: Barcelona consensus meeting. Gynecol Endocrinol 2013; 29:285-291.
3. Johnson J-A, Tough S; Society of Obstetricians and Gynaecologists of Canada. Delayed child-bearing. J Obstet Gynaecol Can 2012; 34:80-93.
4. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917-2931.
5. Rosen A, Rodriguez-Wallberg KA, Rosenzweig L. Psychosocial distress in young cancer survivors. Semin Oncol Nurs 2009; 25:268-277.
6. Canada AL, Schover LR. The psychosocial impact of interrupted childbearing in long-term female cancer survivors. Psychooncology 2012; 21:134-143.
7. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104:386-405.
8. Rosenberg SM, Tamimi RM, Gelber S, et al. Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer 2014; 120:2264-2271.
9. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22:4174-4183.
10. Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014; 32:1151-1156.
11. Senkus E, Gomez H, Dirix L, et al. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psychooncology 2014; 23:173-182.
12. Ruddy KJ, Gelber S, Ginsburg ES, et al. Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors: a comparison to ageand gravidity-matched controls. Menopause 2011; 18:105-108.
13. Gorman JR, Bailey S, Pierce JP, Su HI. How do you feel about fertility and parenthood? The voices of young female cancer survivors. J Cancer Surviv 2012; 6:200-209.
14. Trivers KF, Fink AK, Partridge AH, et al. Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist 2014; 19:814-822.
15. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2013; 31:2500-2510.
16. Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6):vi160-vi170.
17. Partridge AH, Pagani O, Abulkhair O, et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast 2014; 23:209-220.
18. Lambertini M, Anserini P, Levaggi A, et al. Fertility counseling of young breast cancer patients. J Thorac Dis 2013; 5 (Suppl 1):S68-80.
19. Lange S, Tait D, Matthews M. Oncofertility: an emerging discipline in obstetrics and gynecology. Obstet Gynecol Surv 2013; 68:582-593.
20. Azim HA Jr, Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013; 31:73-79.
21. Abusief ME, Missmer SA, Ginsburg ES, et al. Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer. Fertil Steril 2012; 97:154-159.
22. Lavery S, Tsiligiannis S, Carby A. Reproductive options for female cancer patients: balancing hope and realistic expectation. Curr Opin Oncol 2014; 26:501-507.
23. Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2013; 100:1214-1223.
24. Revelli A, Porcu E, Levi Setti PE, et al. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 2013; 29:993-996.
25. Meirow D, Raanani H, Maman E, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril 2014; 102:488-495.
26. Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006; 91:3885-3890.
27. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008; 26:2630-2635.
28. Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 2013; 100:1681-1685.
29. Michaan N, Ben-David G, Ben-Yosef D, et al. Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients. Eur J Obstet Gynecol Reprod Biol 2010; 149:175-177.
30. Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet 2010; 27:491-494.
31. Cao Y-X, Chian R-C. Fertility preservation with immature and in vitro matured oocytes. Semin Reprod Med 2009; 27:456-464.
32. Fadini R, Dal Canto MB, Mignini Renzini M, et al. Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study. Reprod Biomed Online 2009; 19:343-351.
33. Son W-Y, Chung J-T, Herrero B, et al. Selection of the optimal day for oocyte retrieval based on the diameter of the dominant follicle in hCG-primed in vitro maturation cycles. Hum Reprod 2008; 23:2680-2685.
34. Clinic Summary Report. https://www.sartcorsonline.com/rptCSR-PublicMult Year.aspx?ClinicPKID=0. [Accessed 18 October 2014]
35. Bianchi V, Lappi M, Bonu MA, Borini A. Oocyte slow freezing using a 0.2-0.3M sucrose concentration protocol: is it really the time to trash the cryopreservation machine? Fertil Steril 2012; 97:1101-1107.
36. Rienzi L, Cobo A, Paffoni A, et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod 2012; 27:1606-1612.
37. Lee S, Oktay K. Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer? Fertil Steril 2012; 98:961-964.
38. Prasath EB, Chan MLH, Wong WHW, et al. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod 2014; 29:276-278.
39. Alvarez M, SoleM, Devesa M, et al. Live birth using vitrified-warmed oocytes in invasive ovarian cancer: case report and literature review. Reprod Biomed Online 2014; 28:663-668.
40. Rosendahl M, Andersen MT, Ralfkir E, et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010; 94:2186-2190.
41. Sánchez-Serrano M, Novella-Maestre E, Roselló-Sastre E, et al. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod 2009; 24:2238-2243.
42. Rosendahl M, Timmermans Wielenga V, Nedergaard L, et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril 2011; 95:2158-2161.
43. Kim SS, Lee WS, Chung MK, et al. Long-term ovarian function and fertility after heterotopic autotransplantation of cryobanked human ovarian tissue: 8-year experience in cancer patients. Fertil Steril 2009; 91:2349-2354.
44. Donnez J, Dolmans M-M. Preservation of fertility in females with haematological malignancy. Br J Haematol 2011; 154:175-184.
45. Donnez J, Dolmans M-M, Pellicer A, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril 2013; 99:1503-1513.
46. Imbert R, Moffa F, Tsepelidis S, et al. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Hum Reprod 2014; 29:1931-1940.
47. Schmidt KT, Rosendahl M, Ernst E, et al. Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience. Fertil Steril 2011; 95:695-701.
48. Wang LH, Mullen SF, Li Y, et al. Morphological and apoptotic comparison of primordial and primary follicles in cryopreserved human ovarian tissue. Reprod Domest Anim Zuchthyg 2009; 44:879-883.
49. Donnez J, Martinez-Madrid B, Jadoul P, et al. Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update 2006; 12:519-535.
50. Smitz J, Dolmans MM, Donnez J, et al. Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation. Hum Reprod Update 2010; 16:395-414.
51. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009; 91:694-697.
52. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306:269-276.
53. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormonereleasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29:2334-2341.
54. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30:533-538.
55. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009; 117:561-567.
56. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013; 121:78-86.
57. Gilani MM, Hasanzadeh M, Ghaemmaghami F, Ramazanzadeh F. Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy. Asia Pac J Clin Oncol 2007; 3:79-83.
58. Tomasi-Cont N, Lambertini M, Hulsbosch S, et al. Strategies for fertility preservation in young early breast cancer patients. Breast 2014; 23:503-510.
59. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010; 122:803-811.
60. Kim SS, Lee JR, Jee BC, et al. Use of hormonal protection for chemotherapyinduced gonadotoxicity. Clin Obstet Gynecol 2010; 53:740-752.
61. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011; 95:906-914.
62. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011; (11): CD008018.
63. Wang C, Chen M, Fu F, Huang M. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PloS One 2013; 8:e66360.
64. Yang B, Shi W, Yang J, et al. Concurrent treatment with gonadotropinreleasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast 2013; 22:150-157.
65. Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014; 40:675-683.
66. Vitek WS, Shayne M, Hoeger K, et al. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril 2014; 102:808-815; e1.
67. Turner NH, Partridge A, Sanna G, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 2013; 24:2224-2235.
68. Moore HCF, Unger JM, Phillips KA, et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptornegative breast cancer: an international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol 2014; 32:18s; Suppl; abstr LBA505.
69. Lambertini M, Boni L, Michelotti A, et al. Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients. J Clin Oncol 2014; 32:26s; Suppl; abstr 105.
70. Swain SM, Jeong J-H, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362:2053-2065.
71. Wilson C. Reproductive endocrinology: AS101 might prevent chemotherapyinduced infertility. Nat Rev Endocrinol 2013; 9:441.
72. Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and burnout: AS101 prevents follicle loss and preserves fertility. Sci Transl Med 2013; 5:185ra62.
73. Ozalp SS, Yalcin OT, Telli E, et al. Borderline ovarian tumors: outcomes of fertility sparing surgery. Eur J Gynaecol Oncol 2014; 35:154-156.
74. Darai E, Fauvet R, Uzan C, et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update 2013; 19:151-166.
75. Nam J-H. Borderline ovarian tumors and fertility. Curr Opin Obstet Gynecol 2010; 22:227-234.
76. Uzan C, Muller E, Kane A, et al. Fertility sparing treatment of recurrent stage I serous borderline ovarian tumours. Hum Reprod 2013; 28:3222-3226.
77. Mansor S, McCluggage WG. Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases. Int J Gynecol Pathol 2014; 33:470-476.
78. Huber D, Cimorelli V, Usel M, et al. How many ovarian cancer patients are eligible for fertility-sparing surgery? Eur J Obstet Gynecol Reprod Biol 2013; 170:270-274.
79. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007; 110:201-214.
80. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6):vi24-vi32.
81. Morice P, Denschlag D, Rodolakis A, et al. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer 2011; 21:951-963.
82. Fruscio R, Corso S, Ceppi L, et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol 2013; 24:138-144.
83. Zapardiel I, Diestro MD, Aletti G. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol 2014; 40:387-393.
84. Kajiyama H, Mizuno M, Shibata K, et al. Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multiinstitutional study. Eur J Obstet Gynecol Reprod Biol 2014; 175:97-102.
85. Petrillo M, Legge F, Ferrandina G, et al. Fertility-sparing surgery in ovarian cancer extended beyond the ovaries: a case report and review of the literature. Gynecol Obstet Invest 2014; 77:1-5.
86. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12:68-78.
87. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105:812-822.
88. Christinat A, Pagani O. Practical aspects of genetic counseling in breast cancer: lights and shadows. Breast 2013; 22:375-382.
89. Woodson AH, Muse KI, Lin H, et al. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 2014; 19:797-804.
90. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic/Familial High-Risk Assessment: Breast andOvarian genetics-screening.pdf. http://www.nccn.org/profession als/physician-gls/pdf/genetics-screening.pdf. [Accessed 18 October 2014]
91. Balmaña J, Díez O, Rubio IT, Cardoso F; ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl 6):vi31-vi34.
92. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010; 28:240-244.
93. Valentini A, Finch A, Lubinski J, et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol 2013; 31:3914-3919.
94. Derks-Smeets IA, de Die-Smulders CE, Mackens S, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. Breast Cancer Res Treat 2014; 145:673-681.
95. Vadaparampil ST, Quinn GP. Improving communication between oncologists and reproductive specialists to promote timely referral of patients with cancer. J Oncol Pract 2013; 9:300-302.